Three Swedish venture capital firms have provided €16m ($15m) to Inion, a Finnish biomedical company, as biotechnology continues to provide the brightest opportunities for early stage investment.

Many private equity investors that specialise in early stage investment have been forced to attend to their existing portfolio investments over the last two years, particularly those who invested in technology ventures.